News · Cell therapy
Keio and Cyfuse to trial a scaffold-free osteochondral plug

A research group led by Shu Kobayashi at Keio University School of Medicine said on November 18, 2026 that it had developed a base technology for osteochondral regeneration. The work was done jointly with Fujita Health University and Cyfuse Biomedical. A physician-led trial of the three-dimensional cell construct, KCF-BC1, will start at Keio University Hospital. The construct is built by stacking spheroids of allogeneic adipose-derived mesenchymal stromal cells with a bio 3D printer, and uses no synthetic material.
A construct made of cells only, with no scaffold
KCF-BC1 is an osteochondral plug. Spheroids, which are balls of aggregated cells, are stacked at high density by the printer into a construct with thickness. The group says the aim is to regenerate the surface cartilage and the subchondral bone at once from that single construct, and that a patent has been obtained.
Building the graft without a scaffold is what cell sheet engineering does as well, in a flat form rather than a plug. The difference it makes for manufacturing is where the specifications sit. With cells only, the quality attributes have to be set for the starting MSCs, for the spheroids, and for the stacked construct, each in turn. With no scaffold, there is no scaffold material to specify and no degradation rate to match to the pace at which the cells build their own matrix.
The cells come from Rohto Pharmaceutical
The cells used in the trial product are allogeneic human adipose-derived mesenchymal stromal cells supplied by Rohto Pharmaceutical. They are not the patient's own, so the starting material arrives from outside the site.
That puts donor eligibility, the incoming specification for the cells, the cell bank structure and lot-to-lot variability at the center of quality control. MSCs shift with the tissue they come from and with how far they have been passaged, so the conditions that bring the cells to a common state before spheroid formation matter too.
Rabbit and minipig models, then a physician-led trial
The non-clinical work used full-thickness articular cartilage defect models in rabbits and minipigs. The group says the implanted construct integrated with the surrounding tissue and that the full-thickness joint structure, including the subchondral bone, regenerated. The target condition, spontaneous osteonecrosis of the medial femoral condyle, is necrosis of the subchondral bone of the knee that brings pain and deformity.
The trial will run at Keio University Hospital, and its outline is posted on jRCT. The group says it is working toward approval as a regenerative medical product in Japan.
What to settle for an allogeneic construct like this
Both the starting material and the construct need specifications. On the material side: where the donors come from and how they are selected, the incoming tests and limits, what happens when the supplier's lot changes, and how many constructs one lot of cells yields. On the construct side: which of shape, strength, viability and potency carries the specification after stacking, and which assay measures it.
On supply, whether the construct travels frozen or fresh to the operating room changes the whole schedule, and a frozen route needs a way to confirm what the construct is like after thawing. On the plant side, the manufacturing business license category held by the cell processing facility and the timing of the GCTP compliance inspection ahead of a marketing application are worth looking at from the trial stage onward.
Sources
- Base technology developed for a new osteochondral regeneration treatment for spontaneous osteonecrosis of the medial femoral condyle, using a bio 3D printer (Japanese). Cyfuse Biomedical via PR TIMES, Nov 2026.